...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >A comparison of the performance of two penicillin reagent kits in the diagnosis of beta-lactam hypersensitivity.
【24h】

A comparison of the performance of two penicillin reagent kits in the diagnosis of beta-lactam hypersensitivity.

机译：比较两种青霉素试剂盒在诊断β-内酰胺超敏性方面的性能。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Skin testing with penicilloyl polylysine (PPL) and minor determinant mixture (MDM) represents the first-line method for diagnosing beta-lactam hypersensitivity. However, in 2004, Allergopharma and Hollister-Stier announced their decision to stop the production of penicillin reagents (Allergopen and PrePen, respectively) within 1 year. Therefore, we decided to compare PPL and MDM from Allergopharma (Allergopen) with those from Diater (DAP). METHODS: We skin-tested 195 subjects with both Allergopen and DAP reagents, as well as with other beta-lactams; 74 (group A) had had immediate reactions to beta-lactams and 74 (group B) nonimmediate reactions, while 47 (group C) underwent prophylactic tests. RESULTS: One hundred two patients (52.3%) had positive skin tests; 29 (14.9%) were positive to PPL and/or MDM. Of the 102 skin-test-positive patients, 44 belonged to group A, 57 to B and 1 to C; the last was positive only to Allergopen PPL (PPL-A) and tolerated the benzylpenicillin challenge. Minor determinant mixture reagents produced identical results in the 148 patients of groups A and B, 22 (14.9%) of which were positive. Both PPL reagents produced negative results in 139 of these 148 patients and positive ones in 5; one subject was positive to DAP PPL (PPL-D) and negative to PPL-A, while three patients were positive to PPL-A and negative to PPL-D; two of the latter tolerated benzylpenicillin challenges. CONCLUSIONS: Minor determinant mixture reagents produced identical results in all 195 patients. Results of skin testing with PPL reagents were concordant in 190 (97.4%) of them. Therefore, DAP reagents are a reliable alternative to Allergopen ones.
机译：背景：用青霉酰聚赖氨酸（PPL）和次要决定簇混合物（MDM）进行皮肤测试是诊断β-内酰胺超敏反应的一线方法。但是，在2004年，Allergopharma和Hollister-Stier宣布了他们决定在1年内停止生产青霉素试剂（分别为Allergopen和PrePen）的决定。因此，我们决定将Allergopharma（Allergopen）的PPL和MDM与Diater（DAP）的进行比较。方法：我们对195名受试者进行了Allergopen和DAP试剂以及其他β-内酰胺类药物的皮肤测试; 74（A组）对β-内酰胺类有立即反应，74（B组）非直接反应，而47（C组）进行了预防性测试。结果：102例患者（52.3％）的皮肤试验阳性; PPL和/或MDM阳性29例（14.9％）。在102名皮肤试验阳性患者中，有44人属于A组，其中57人属于B组，而1人属于C组。最后一个仅对Allergopen PPL（PPL-A）呈阳性，并能耐受苄青霉素的攻击。次要决定因素混合试剂在A组和B组的148例患者中产生了相同的结果，其中22例（14.9％）为阳性。两种PPL试剂在148例患者中有139例阴性，在5例中阳性。一名受试者对DAP PPL（PPL-D）阳性，对PPL-A阴性，而三名患者对PPL-A阳性，对PPL-D阴性;后者中的两个耐受苄青霉素挑战。结论：在全部195例患者中，次决定性混合试剂产生的结果相同。用PPL试剂进行的皮肤测试结果与190（97.4％）相一致。因此，DAP试剂是Allergopen试剂的可靠替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号